IP Library › Granted Patent US 11,814,642
Granted Patent B2
US 11,814,642 · App. 17/848,307 · Granted Nov 14, 2023

Manufacturing and use of recombinant AAV vectors

Inventors: Matthias Charles Jerome Hebben (Lexington, MA); Jing Liao (Lexington, MA); Carmen Wu (Cambridge, MA); Wilhad Hans Reuter (Chestnut Hill, MA); Thomas Matthew Edwards (Littleton, MA)
Assignee: LogicBio Therapeutics, Inc.
C12N15/86C12N2750/14143C12N2750/14151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,814,642
App. No.
17/848,307
Granted
Nov 14, 2023
Kind
B2
Abstract

Presented herein are technologies and methods for improved production of AAV vectors.

Claims (29)

1. A transfection system for the production of AAV vectors, the system comprising;

a closed, circular DNA plasmid consisting of a polynucleotide sequence of SEQ ID NO:2 as a Rep/Helper plasmid; and

a Payload/Cap plasmid consisting of a polynucleotide sequence of SEQ ID NO: 11, a polynucleotide sequence encoding a Cap gene and a polynucleotide sequence encoding a transgene,

wherein the polynucleotide sequence encoding the Cap gene is inserted before position 2025 of SEQ ID NO:11, and

wherein the polynucleotide sequence encoding the transgene is inserted after position 2663 of SEQ ID NO: 11.

2. The transfection system of claim 1 , wherein the plasmid ratio of the Rep/Helper plasmid to the Payload/Cap plasmid is 1.5:1 up to 10:1.

3. The transfection system of claim 2 , wherein the transfection system comprises no plasmid other than the Rep/Helper plasmid and the Payload/Cap plasmid.

4. The transfection system of claim 1 , wherein the transfection system comprises no plasmid other than the Rep/Helper plasmid and the Payload/Cap plasmid.

5. A method of producing an AAV vector in a cell line, the method comprising the step of transfecting the cell line with only two unique plasmids in the presence of a transfection reagent, the two plasmids consisting of:

(a) a closed, circular DNA plasmid consisting of a polynucleotide sequence of SEQ ID NO:2 as a first plasmid, and

(b) a second Payload/Cap plasmid consisting of a polynucleotide sequence of SEQ ID NO:11, a polynucleotide sequence encoding a Cap gene, and a polynucleotide sequence encoding a transgene,

wherein the polynucleotide sequence encoding the Cap gene is inserted before positions 2025 of SEQ ID NO:11, and

wherein the polynucleotide sequence encoding the transgene is inserted after position 2663 of SEQ ID NO:11

wherein the transfected cell line expresses the plasmids to produce the AAV vector.

6. The method of claim 5 , wherein the cell line is a HEK293 cell line.

7. The method of claim 5 , wherein the transfection reagent is a cationic polymer reagent.

8. The method of claim 5 , wherein the method comprises transfecting the cell line with the first plasmid and the second plasmid with a plasmid ratio of about 1.5:1 to 10:1.

9. The method of claim 8 , wherein the method comprises transfecting the cell line with the first plasmid and the second plasmid with a plasmid ratio of about 1.5:1.

10. The method of claim 8 , wherein

(a) the cell line is a HEK293 cell line; and

(b) the Transfection Reagent is a cationic polymer reagent.

11. The method of claim 10 , wherein the method comprises transfecting the cell line with the first plasmid and the second plasmid with a plasmid ratio of about 1.5:1.

12. The method of claim 10 , wherein the cell line is HEK293F.

13. A method of expressing producing an AAV vector in a HEK293 cell line, the method comprising the step of transfecting the cell line with only two unique plasmids in the presence of a transfection reagent, the two plasmids consisting of:

(a) a closed, circular DNA plasmid consisting of a polynucleotide sequence of SEQ ID NO:2 as a Rep/Helper plasmid, and

(b) a Payload/Cap plasmid consisting of a polynucleotide sequence of SEQ ID NO:11, a polynucleotide sequence encoding a Cap gene, and a polynucleotide sequence encoding a transgene,

wherein the polynucleotide sequence encoding the Cap gene is inserted before position 2025 of SEQ ID NO:11, and

wherein the polynucleotide sequence encoding the transgene is inserted after position 2663 of SEQ ID NO:11; and wherein the HEK293 cell line is transfected with the Rep/Helper plasmid and the Payload/Cap plasmid with a plasmid ratio of about 1.5:1 to 10:1 and in the absence of any other Rep/helper or Payload/Cap Plasmid,

wherein the transfected HEK293 cell line expresses the plasmids to produce the AAV vector.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2022
From: HEBBEN, MATTHIAS CHARLES JEROME; LIAO, JING; WU, CARMEN; REUTER, WILHAD HANS; EDWARDS, THOMAS MATTHEW
To: LOGICBIO THERAPEUTICS, INC.
Reel/Frame 060744/0140 →
Continuity (5)
Continuation PCTUS2022017901 · Feb 25, 2022
Provisional Application 63257036 · Oct 18, 2021
Provisional Application 63234610 · Aug 18, 2021
Provisional Application 63154474 · Feb 26, 2021
Related Publication 20230111556A1 · Apr 13, 2023
Cited By (1)
US 12,290,574